INMB (INmune Bio) Long-Term Debt: $0.00 Mil (As of Mar. 2026)


INMB INmune Bio Inc INMB
57 GF Score
Price $1.70
GF Value $1.83
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is INmune Bio Long-Term Debt?

INmune Bio INMB +1.19% 57 Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates INMB with a GF Score™ of 57/100 and a GF Value™ of $1.83 (Fairly Valued). The stock has 5 warning signs investors should review.

INmune Bio's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

INmune Bio  (NAS:INMB) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

INmune Bio Long-Term Debt Related Terms

INmune Bio Long-Term Debt Historical Data

* Premium members only.

The historical data trend for INmune Bio's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

INmune Bio Long-Term Debt Chart

INmune Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.46 9.70 0.00 0.00 0.00

INmune Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
INMB
57GF Score
INmune Bio Inc INMB
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
INmune Bio (INMB) has a Long-Term Debt of $0.00 Mil as of Mar. 2026.
Is INmune Bio's Long-Term Debt too high?
INmune Bio's current Long-Term Debt is $0.00 Mil. Overall, INmune Bio has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's Long-Term Debt compare to GRCE and NTRB?
INmune Bio's Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. INmune Bio's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Fairly Valued. The stock's GF Value™ is $1.83, compared to a current price of $1.70 — trading 7.1% below its estimated fair value. The current Long-Term Debt is $0.00 Mil. INmune Bio's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For INmune Bio (INMB), the current Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is INmune Bio (INMB) Overvalued in 2026?

Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued. The current stock price of $1.70 is trading 7.1% below its estimated GF Value™ of $1.83. GuruFocus considers INmune Bio to be Fairly Valued.

Key valuation signals for INMB:

  • Long-Term Debt: $0.00 Mil
  • GF Value™: $1.83 vs. price of $1.70 (7.1% below fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

INmune Bio Business Description

Address 225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
57GF Score

Get the complete analysis for INMB

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.70
Price
$1.83
GF Value